ArticleBMC research notes2025
Multiple sclerosis patient-reported outcomes of pharmacotherapy clinic drug utilization programs; a controlled pre-post study of self-injectable disease-modifying therapies.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPharmacists are the key members of the multidisciplinary healthcare team for patients with multiple sclerosis (MS) and inappropriate utilization of medications and devices. This study aimed to observe the clinical value of pharmacist educational intervention (PEI) to optimize the use of interferon-βs in Iranian patients with MS through the involvement of the pharmacotherapy clinic in Shahid Kazemi specialty pharmacy in drug utilization programs.
methodsThis study received ethical approval from the Research Ethics Committee of the School of Pharmacy at Shahid Beheshti University of Medical Sciences, under approval ID IR.SBMU.PHARMACY.REC.1398.240. In this controlled pre-post survey a questionnaire consisting of 17 items assesses the patient's knowledge on the correct use of interferon-βs and the actions needed to reduce the adverse effects (AEs) of the medication and improve the control of the disease symptoms. After testing the questionnaire's validity and reliability based on the opinions of a multidisciplinary expert panel, 15 items remained. 100 patients, who were diagnosed with MS and receiving interferon-βs for at least one year, responded to the questionnaire before and after the PEI.
resultsPatients' scores before and after receiving the educational program were 4.90 ± 5.79 and 14.44 ± 0.99, respectively. The results show that most participants do not have satisfying knowledge about their interferons, although they have injected them for more than one year, and there is a significant difference between the knowledge before and after the PEI (P < 0.001).
conclusionOur results showed that PEI could improve the pharmacotherapeutic knowledge and awareness of patients with MS about their disease-modifying therapies. Pharmacist-provided managed care is crucial in optimizing patient outcomes and the clinical burden of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.